查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1445535

慢性乙型肝炎市場評估：依藥物類別、性別、通路、地區、機會與預測（2017-2031）

Chronic Hepatitis B Market Assessment, By Drug Class [Immune Modulators, Antivirals], By Gender [Male, Female], By Distribution Channel [Hospital Pharmacies, Retail Pharmacies, Online Pharmacies] By Region, Opportunities and Forecast, 2017-2031F
出版日期: | 出版商: Market Xcel - Markets and Data | 英文 236 Pages | 商品交期: 3-5個工作天內

價格

全球慢性B型肝炎市場規模將從 2023 年的 50.1 億美元增至 2031 年的 65.8 億美元，複合年增長率為 3.46%，預計在 2024-2031 年預測期內將增長至 .

市場的成長得益於製藥業投資的增加、評估慢性乙型肝炎各種治療方法安全性和有效性的研發活動的增加以及設施使用情況的改善。

根據肯塔基大學和梅奧診所研究人員發表的 StatPearls 文章，全世界約有 350 至 4 億人患有慢性乙型肝炎。 由於慢性B型肝炎盛行率不斷上升，預計未來幾年市場將顯著成長。 增加對新治療和診斷解決方案開發的投資進一步支持市場擴張。

先進診斷解決方案的部署將推動市場發展

B型肝炎便捷診斷解決方案的開發進展正在支持市場成長。 朱拉隆功大學的研發團隊開發了一種針對乙型肝炎表面抗原的無線檢測系統，使用可由智慧型手機控制的創新電化學卡感測器。 這種簡單的無標記電化學平台支援便捷的即時診斷操作。

增加研發活動支持市場發展

研發活動在開發慢性B型肝炎等疾病的治療方法方面發揮著重要作用。 研發活動使研究人員能夠了解新藥如何在患者中發揮作用，並將其與現有的治療方法進行比較。 它還可以幫助您了解不同的治療途徑。

北美預計將佔有很大的市場份額

多家領先公司的存在和發達的醫療基礎設施正在支持北美市場的成長。 根據美國衛生與公共服務部統計，美國約有 88 萬至 189 萬人感染慢性B型肝炎。

本報告調查了全球慢性乙型肝炎市場，提供了市場定義和概述、市場規模趨勢和預測、各個細分市場和地區的詳細分析、行業結構以及影響市場成長的因素。分析、案例研究、競爭格局、以及主要公司的簡介。

目錄

第 1 章研究方法

第 2 章專案範圍與定義

第 3 章執行摘要

第 4 章全球慢性B型肝炎市場展望

  • 市場規模/預測
  • 依藥物類別
    • 免疫調節劑
    • 抗病毒藥物
  • 性別
    • 男性
    • 女性
  • 按分銷管道
    • 醫院藥房
    • 零售藥局
    • 網路藥局
  • 按地區
    • 北美
    • 歐洲
    • 亞太地區
    • 南美洲
    • 中東/非洲
  • 各公司的市佔率

第 5 章全球慢性B型肝炎市場展望：按地區

  • 北美
  • 歐洲
  • 亞太地區
  • 南美洲
  • 中東/非洲

第 6 章市場映射

  • 依藥物類別
  • 性別
  • 按分銷管道
  • 按地區

第 7 章宏觀環境與產業結構

  • 需求與供給分析
  • 匯入/匯出分析
  • 價值鏈分析
  • PESTEL 分析
  • 波特五力分析

第 8 章市場動態

  • 生長促進因素
  • 生長抑制因素（問題、限制因素）

第 9 章監理架構與創新

  • 專利情況
  • 監理機關的核准
  • 創新/新興技術

第 10 章主要公司狀況

  • 前 5 名市場領導者的競爭矩陣
  • 前 5 位市場領導者的市場收入分析
  • 併購/合資企業（如果適用）
  • SWOT 分析（5 家參與公司）
  • 專利分析（如果適用）

第 11 章價格分析

第 12 章案例研究

第 13 章主要公司展望

  • Gilead Sciences, Inc.
  • GlaxoSmithKline Pharmaceuticals Ltd.
  • F. Hoffmann-La Roche AG
  • Novartis AG
  • Bristol Myers Squibb Co.
  • Vir Biotechnology
  • Virion Therapeutics, LLC
  • Beijing Continent Pharmaceutical Co. Ltd.
  • GlobeImmune, Inc.
  • Viatris Inc.

第 14 章策略建議

第 15 章關於我們公司/免責聲明

Product Code: MX11084

Global chronic hepatitis B market is projected to witness a CAGR of 3.46% during the forecast period, 2024-2031, growing from USD 5.01 billion in 2023 to USD 6.58 billion in 2031F. The expansion of the market is supported by increasing investments in the pharmaceutical sector, rising research and development activities to evaluate the safety and efficacy of various treatments available for chronic hepatitis B, and growing accessibility to healthcare facilities.

According to a StatPearls' article published by researchers of University of Kentucky and Mayo Clinic stated that approximately 350-400 million individuals across the globe suffer from chronic hepatitis B. Early detection of the infection can aid in management of the condition and prevention of complications. Due to the increasing prevalence of chronic hepatitis B, the market is expected to witness significant growth in the coming years. Increasing investments towards the development of novel treatment and diagnostic solutions is further supporting the market expansion.

As per the Centers for Disease Control and Prevention, 25% of cases of chronic hepatitis B progress into liver cancer. Due to the severity of chronic infection, various research and development activities are underway across the globe. For instance, National Taiwan University Hospital is conducting an interventional, randomized, active control study to compare P1101 to entecavir in subjects with HBeAg-negative chronic hepatitis B. The subjects of the study were randomized in 2:1 ratio for P1101: entecavir with the help of a computer-generated permuted block randomization scheme. The study is expected to conclude in December 2024.

Deployment of Advanced Diagnostic Solutions to Boost the Market

The increasing development of convenient diagnostic solutions for hepatitis B is supporting the growth of the market. A team of researchers from Chulalongkorn University developed a wireless-based detection system using innovative electrochemical card sensors that can be controlled by a smartphone for targeting hepatitis B surface antigens. The simple label-free electrochemical platform will aid in convenient operation for point of care diagnosis. Point of care testing is a system that is designed for complete diagnostic platforms to enhance patient outcomes by significantly reducing sample-to-answer time. The device is based on a novel electrochemical sensor architecture. The analytical performance of the system was evaluated with the help of a dilution series of hepatitis B surface antigen titers. The electrochemical card sensor was engineered as a portable potentiostat that was controlled using a wireless Near Field Communication (NFC) network connection of smartphone.

Increasing Research and Development Activities Support Market Growth

Research and development activities play a crucial role in the development of treatments for diseases including chronic hepatitis B. They allow researchers to understand how new medicines work in patients and compare them to the already available treatments. They can aid in understanding the pathways of various treatments. For instance, an observational study is being conducted by the Chinese University of Hong Kong to evaluate the fast-track treatment pathways under primary care for patients suffering from chronic hepatitis B. The analyses will be performed before and after the introduction of pathways in the retrospective-prospective longitudinal cohort study, with comparisons made to unexposed controls. The novel fast-track treatment pathway for patients under primary care will bridge the gap and provide pivotal data to the Steering Committee and the Government for guiding the strategies to achieve the goals set by the World Health Organization (WHO). Various clinical trials are being initiated to determine potential treatment solutions for people living with chronic hepatitis B infection. GlaxoSmithKline is about to launch two new phase 3 trails namely, B Well-1 and B Well-2. The trials will test an experimental drug as a potential treatment option for hepatitis B.

North America Anticipated to Account Significant Market Share

The presence of several leading market players in the region along with a well-established healthcare infrastructure is supporting the market expansion in North America. Furthermore, the increasing prevalence of the disease in the United States is bolstering the demand for treatment solutions for chronic hepatitis B. According to the US Department of Health and Human Services, approximately 880,000 to 1.89 million individuals in the United States are chronically infected with the hepatitis B virus.

Growing efforts of regional market players are further supporting the market expansion in North America. For instance, in October 2023, Virion Therapeutics dosed the first patients in their Phase Ib trial that will investigate VRON-0200 as the functional cure for chronic hepatitis B. VRON-0200 will use Virion's checkpoint modifiers for broadening and amplifying the patient's T cell response against hepatitis B virus infection. Over the course of the preclinical studies, the drug showcased the ability to switch on T cells that are generally not activated during chronic hepatitis B infection. The program is being conducted with the help of Ocean Biomedical, their joint venture partner.

Antivirals to Account for Significant Market Share

The segment held a major share of the market during the historical period and is expected to generate similar results over the forecast period owing to the increasing prevalence of the disease and rapid improvements in the healthcare infrastructure. Various studies are underway to determine the safety and effectiveness of antiviral therapies on patients with chronic hepatitis B. For instance, a phase 2 interventional study is being conducted by Sun Yat-sen University to determine the effectiveness and safety of entecavir, in combination with tenofovir amibufenamide. Over the course of the study, the investigators plan to divide the patients randomly into two groups. Group A will be treated with entecavir whereas group B will be treated with tenofovir amibufenamide and entecavir. The patients in both groups will be followed up for ninety-six weeks. The primary endpoint of the study involves the comparison of the inhibition rate of HBV-DNA between both groups. The secondary endpoint of the study includes a comparison of adverse side effects, a comparison in decrease of HBV DNA at forty-eight weeks, changes of HBsAg at fort-eight and ninety-six weeks and comparison of HBeAg seroconversion rates between the two groups.

Retail Pharmacies to Dominate the Market Share

The increasing popularity of retail pharmacies in various regions across the globe can be attributed to the availability of both branded and generic drugs across these distribution channels. The pharmacists play a crucial role in providing counseling to the patients and explaining various side-effects associated with the consumption of the medication. These pharmacies play a significant role in the healthcare ecosystem in various countries.

On the contrary, online pharmacies are expected to witness significant growth in the coming years. As per a survey funded by Sanofi Consumer Healthcare, respondents highlighted the various advantages associated with shopping across online pharmacies including convenience and reduced costs for patients. The growing acceptance of the distribution channels due to increasing awareness about legitimate and verified online pharmacies is further supporting the expansion of the segment.

Future Market Scenario

Several clinical trials are underway to evaluate novel drugs with different mechanisms of action, with promising results. There is an emerging multitude of new molecules individually and in combination, that can act as future treatment strategies. Investments are increasing toward the development of novel treatment solutions. For instance, in December 2023, Tune Therapeutics, a Duke Capital Partners portfolio company and Duke University start-up announced that they were working on a potentially curative and new approach to treating chronic hepatitis B infection. The Tune HBV program was unveiled in November 2023, at the University of Auckland at the American Association for the Study of Liver Diseases (AASLD) conference in Boston. Tune Therapeutics aims to dose their first patient in 2024, with Dr Gane Professor of Medicine at the University of Auckland serving as the lead investigator.

Key Players Landscape and Outlook

Increasing investments towards research and development activities by the key players of the market along with the provision of fast-track status by FDA is supporting the market expansion.

In 2024, FDA granted fast track status to bepirovirsen, a triple action investigational antisense oligonucleotide, developed by GlaxoSmithKline for treating chronic hepatitis B. Developed jointly with Ionis Pharmaceuticals, the drug is intended to stimulate the immune system, curb viral DNA replication and reduce the levels of hepatitis B surface antigens to boost the chances of a sustained and durable response.

Table of Contents

1. Research Methodology

2. Project Scope & Definitions

3. Executive Summary

4. Global Chronic Hepatitis B Market Outlook, 2017-2031F

  • 4.1. Market Size & Forecast
    • 4.1.1. By Value
    • 4.1.2. By Volume
  • 4.2. By Drug Class
    • 4.2.1. Immune Modulators
    • 4.2.2. Antivirals
  • 4.3. By Gender
    • 4.3.1. Male
    • 4.3.2. Female
  • 4.4. By Distribution Channel
    • 4.4.1. Hospital Pharmacies
    • 4.4.2. Retail Pharmacies
    • 4.4.3. Online Pharmacies
  • 4.5. By Region
    • 4.5.1. North America
    • 4.5.2. South America
    • 4.5.3. Europe
    • 4.5.4. Asia-Pacific
    • 4.5.5. Middle East & Africa
  • 4.6. By Company Market Share (%), 2023

5. Global Chronic Hepatitis B Market Outlook, By Region, 2017-2031F

  • 5.1. North America*
    • 5.1.1. Market Size & Forecast
      • 5.1.1.1. By Value
      • 5.1.1.2. By Volume
    • 5.1.2. By Drug Class
      • 5.1.2.1. Immune Modulators
      • 5.1.2.2. Antivirals
    • 5.1.3. By Gender
      • 5.1.3.1. Male
      • 5.1.3.2. Female
    • 5.1.4. By Distribution Channel
      • 5.1.4.1. Hospital Pharmacies
      • 5.1.4.2. Retail Pharmacies
      • 5.1.4.3. Online Pharmacies
    • 5.1.5. United States*
      • 5.1.5.1. Market Size & Forecast
      • 5.1.5.1.1. By Value
      • 5.1.5.1.2. By Volume
      • 5.1.5.2. By Drug Class
      • 5.1.5.2.1. Immune Modulators
      • 5.1.5.2.2. Antivirals
      • 5.1.5.3. By Gender
      • 5.1.5.3.1. Male
      • 5.1.5.3.2. Female
      • 5.1.5.4. By Distribution Channel
      • 5.1.5.4.1. Hospital Pharmacies
      • 5.1.5.4.2. Retail Pharmacies
      • 5.1.5.4.3. Online Pharmacies
    • 5.1.6. Canada
    • 5.1.7. Mexico

All segments will be provided for all regions and countries covered

  • 5.2. Europe
    • 5.2.1. Germany
    • 5.2.2. France
    • 5.2.3. Italy
    • 5.2.4. United Kingdom
    • 5.2.5. Russia
    • 5.2.6. Netherlands
    • 5.2.7. Spain
    • 5.2.8. Turkey
    • 5.2.9. Poland
  • 5.3. Asia-Pacific
    • 5.3.1. India
    • 5.3.2. China
    • 5.3.3. Japan
    • 5.3.4. Australia
    • 5.3.5. Vietnam
    • 5.3.6. South Korea
    • 5.3.7. Indonesia
    • 5.3.8. Philippines
  • 5.4. South America
    • 5.4.1. Brazil
    • 5.4.2. Argentina
  • 5.5. Middle East & Africa
    • 5.5.1. Saudi Arabia
    • 5.5.2. UAE
    • 5.5.3. South Africa

6. Market Mapping, 2023

  • 6.1. By Drug Class
  • 6.2. By Gender
  • 6.3. By Distribution Channel
  • 6.4. By Region

7. Macro Environment and Industry Structure

  • 7.1. Supply Demand Analysis
  • 7.2. Import Export Analysis
  • 7.3. Value Chain Analysis
  • 7.4. PESTEL Analysis
    • 7.4.1. Political Factors
    • 7.4.2. Economic System
    • 7.4.3. Social Implications
    • 7.4.4. Technological Advancements
    • 7.4.5. Environmental Impacts
    • 7.4.6. Legal Compliances and Regulatory Policies (Statutory Bodies Included)
  • 7.5. Porter's Five Forces Analysis
    • 7.5.1. Supplier Power
    • 7.5.2. Buyer Power
    • 7.5.3. Substitution Threat
    • 7.5.4. Threat from New Entrant
    • 7.5.5. Competitive Rivalry

8. Market Dynamics

  • 8.1. Growth Drivers
  • 8.2. Growth Inhibitors (Challenges and Restraints)

9. Regulatory Framework and Innovation

  • 9.1. Patent Landscape
  • 9.2. Regulatory Approvals
  • 9.3. Innovations/Emerging Technologies

10. Key Players Landscape

  • 10.1. Competition Matrix of Top Five Market Leaders
  • 10.2. Market Revenue Analysis of Top Five Market Leaders (in %, 2023)
  • 10.3. Mergers and Acquisitions/Joint Ventures (If Applicable)
  • 10.4. SWOT Analysis (For Five Market Players)
  • 10.5. Patent Analysis (If Applicable)

11. Pricing Analysis

12. Case Studies

13. Key Players Outlook

  • 13.1. Gilead Sciences, Inc.
    • 13.1.1. Company Details
    • 13.1.2. Key Management Personnel
    • 13.1.3. Products & Services
    • 13.1.4. Financials (As reported)
    • 13.1.5. Key Market Focus & Geographical Presence
    • 13.1.6. Recent Developments
  • 13.2. GlaxoSmithKline Pharmaceuticals Ltd.
  • 13.3. F. Hoffmann-La Roche AG
  • 13.4. Novartis AG
  • 13.5. Bristol Myers Squibb Co.
  • 13.6. Vir Biotechnology
  • 13.7. Virion Therapeutics, LLC
  • 13.8. Beijing Continent Pharmaceutical Co. Ltd.
  • 13.9. GlobeImmune, Inc.
  • 13.10. Viatris Inc.

Companies mentioned above DO NOT hold any order as per market share and can be changed as per information available during research work

14. Strategic Recommendations

15. About Us & Disclaimer

List of Tables

  • Table 1. Pricing Analysis of Products from Key Players
  • Table 2. Competition Matrix of Top 5 Market Leaders
  • Table 3. Mergers & Acquisitions/ Joint Ventures (If Applicable)
  • Table 4. About Us - Regions and Countries Where We Have Executed Client Projects

List of Figures

  • Figure 1. Global Chronic Hepatitis B Market, By Value, in USD Billion, 2017-2031F
  • Figure 2. Global Chronic Hepatitis B Market, By Volume, in Million Units, 2017-2031F
  • Figure 3. Global Chronic Hepatitis B Market Share (%), By Drug Class, 2017-2031F
  • Figure 4. Global Chronic Hepatitis B Market Share (%), By Gender, 2017-2031F
  • Figure 5. Global Chronic Hepatitis B Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 6. Global Chronic Hepatitis B Market Share (%), By Region, 2017-2031F
  • Figure 7. North America Chronic Hepatitis B Market, By Value, in USD Billion, 2017-2031F
  • Figure 8. North America Chronic Hepatitis B Market, By Volume, in Million Units, 2017-2031F
  • Figure 9. North America Chronic Hepatitis B Market Share (%), By Drug Class, 2017-2031F
  • Figure 10. North America Chronic Hepatitis B Market Share (%), By Gender, 2017-2031F
  • Figure 11. North America Chronic Hepatitis B Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 12. North America Chronic Hepatitis B Market Share (%), By Country, 2017-2031F
  • Figure 13. United States Chronic Hepatitis B Market, By Value, in USD Billion, 2017-2031F
  • Figure 14. United States Chronic Hepatitis B Market, By Volume, in Million Units, 2017-2031F
  • Figure 15. United States Chronic Hepatitis B Market Share (%), By Drug Class, 2017-2031F
  • Figure 16. United States Chronic Hepatitis B Market Share (%), By Gender, 2017-2031F
  • Figure 17. United States Chronic Hepatitis B Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 18. Canada Chronic Hepatitis B Market, By Value, in USD Billion, 2017-2031F
  • Figure 19. Canada Chronic Hepatitis B Market, By Volume, in Million Units, 2017-2031F
  • Figure 20. Canada Chronic Hepatitis B Market Share (%), By Drug Class, 2017-2031F
  • Figure 21. Canada Chronic Hepatitis B Market Share (%), By Gender, 2017-2031F
  • Figure 22. Canada Chronic Hepatitis B Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 23. Mexico Chronic Hepatitis B Market, By Value, in USD Billion, 2017-2031F
  • Figure 24. Mexico Chronic Hepatitis B Market, By Volume, in Million Units, 2017-2031F
  • Figure 25. Mexico Chronic Hepatitis B Market Share (%), By Drug Class, 2017-2031F
  • Figure 26. Mexico Chronic Hepatitis B Market Share (%), By Gender, 2017-2031F
  • Figure 27. Mexico Chronic Hepatitis B Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 28. Europe Chronic Hepatitis B Market, By Value, in USD Billion, 2017-2031F
  • Figure 29. Europe Chronic Hepatitis B Market, By Volume, in Million Units, 2017-2031F
  • Figure 30. Europe Chronic Hepatitis B Market Share (%), By Drug Class, 2017-2031F
  • Figure 31. Europe Chronic Hepatitis B Market Share (%), By Gender, 2017-2031F
  • Figure 32. Europe Chronic Hepatitis B Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 33. Europe Chronic Hepatitis B Market Share (%), By Country, 2017-2031F
  • Figure 34. Germany Chronic Hepatitis B Market, By Value, in USD Billion, 2017-2031F
  • Figure 35. Germany Chronic Hepatitis B Market, By Volume, in Million Units, 2017-2031F
  • Figure 36. Germany Chronic Hepatitis B Market Share (%), By Drug Class, 2017-2031F
  • Figure 37. Germany Chronic Hepatitis B Market Share (%), By Gender, 2017-2031F
  • Figure 38. Germany Chronic Hepatitis B Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 39. France Chronic Hepatitis B Market, By Value, in USD Billion, 2017-2031F
  • Figure 40. France Chronic Hepatitis B Market, By Volume, in Million Units, 2017-2031F
  • Figure 41. France Chronic Hepatitis B Market Share (%), By Drug Class, 2017-2031F
  • Figure 42. France Chronic Hepatitis B Market Share (%), By Gender, 2017-2031F
  • Figure 43. France Chronic Hepatitis B Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 44. Italy Chronic Hepatitis B Market, By Value, in USD Billion, 2017-2031F
  • Figure 45. Italy Chronic Hepatitis B Market, By Volume, in Million Units, 2017-2031F
  • Figure 46. Italy Chronic Hepatitis B Market Share (%), By Drug Class, 2017-2031F
  • Figure 47. Italy Chronic Hepatitis B Market Share (%), By Gender, 2017-2031F
  • Figure 48. Italy Chronic Hepatitis B Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 49. United Kingdom Chronic Hepatitis B Market, By Value, in USD Billion, 2017-2031F
  • Figure 50. United Kingdom Chronic Hepatitis B Market, By Volume, in Million Units, 2017-2031F
  • Figure 51. United Kingdom Chronic Hepatitis B Market Share (%), By Drug Class, 2017-2031F
  • Figure 52. United Kingdom Chronic Hepatitis B Market Share (%), By Gender, 2017-2031F
  • Figure 53. United Kingdom Chronic Hepatitis B Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 54. Russia Chronic Hepatitis B Market, By Value, in USD Billion, 2017-2031F
  • Figure 55. Russia Chronic Hepatitis B Market, By Volume, in Million Units, 2017-2031F
  • Figure 56. Russia Chronic Hepatitis B Market Share (%), By Drug Class, 2017-2031F
  • Figure 57. Russia Chronic Hepatitis B Market Share (%), By Gender, 2017-2031F
  • Figure 58. Russia Chronic Hepatitis B Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 59. Netherlands Chronic Hepatitis B Market, By Value, in USD Billion, 2017-2031F
  • Figure 60. Netherlands Chronic Hepatitis B Market, By Volume, in Million Units, 2017-2031F
  • Figure 61. Netherlands Chronic Hepatitis B Market Share (%), By Drug Class, 2017-2031F
  • Figure 62. Netherlands Chronic Hepatitis B Market Share (%), By Gender, 2017-2031F
  • Figure 63. Netherlands Chronic Hepatitis B Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 64. Spain Chronic Hepatitis B Market, By Value, in USD Billion, 2017-2031F
  • Figure 65. Spain Chronic Hepatitis B Market, By Volume, in Million Units, 2017-2031F
  • Figure 66. Spain Chronic Hepatitis B Market Share (%), By Drug Class, 2017-2031F
  • Figure 67. Spain Chronic Hepatitis B Market Share (%), By Gender, 2017-2031F
  • Figure 68. Spain Chronic Hepatitis B Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 69. Turkey Chronic Hepatitis B Market, By Value, in USD Billion, 2017-2031F
  • Figure 70. Turkey Chronic Hepatitis B Market, By Volume, in Million Units, 2017-2031F
  • Figure 71. Turkey Chronic Hepatitis B Market Share (%), By Drug Class, 2017-2031F
  • Figure 72. Turkey Chronic Hepatitis B Market Share (%), By Gender, 2017-2031F
  • Figure 73. Turkey Chronic Hepatitis B Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 74. Poland Chronic Hepatitis B Market, By Value, in USD Billion, 2017-2031F
  • Figure 75. Poland Chronic Hepatitis B Market, By Volume, in Million Units, 2017-2031F
  • Figure 76. Poland Chronic Hepatitis B Market Share (%), By Drug Class, 2017-2031F
  • Figure 77. Poland Chronic Hepatitis B Market Share (%), By Gender, 2017-2031F
  • Figure 78. Poland Chronic Hepatitis B Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 79. South America Chronic Hepatitis B Market, By Value, in USD Billion, 2017-2031F
  • Figure 80. South America Chronic Hepatitis B Market, By Volume, in Million Units, 2017-2031F
  • Figure 81. South America Chronic Hepatitis B Market Share (%), By Drug Class, 2017-2031F
  • Figure 82. South America Chronic Hepatitis B Market Share (%), By Gender, 2017-2031F
  • Figure 83. South America Chronic Hepatitis B Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 84. South America Chronic Hepatitis B Market Share (%), By Country, 2017-2031F
  • Figure 85. Brazil Chronic Hepatitis B Market, By Value, in USD Billion, 2017-2031F
  • Figure 86. Brazil Chronic Hepatitis B Market, By Volume, in Million Units, 2017-2031F
  • Figure 87. Brazil Chronic Hepatitis B Market Share (%), By Drug Class, 2017-2031F
  • Figure 88. Brazil Chronic Hepatitis B Market Share (%), By Gender, 2017-2031F
  • Figure 89. Brazil Chronic Hepatitis B Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 90. Argentina Chronic Hepatitis B Market, By Value, in USD Billion, 2017-2031F
  • Figure 91. Argentina Chronic Hepatitis B Market, By Volume, in Million Units, 2017-2031F
  • Figure 92. Argentina Chronic Hepatitis B Market Share (%), By Drug Class, 2017-2031F
  • Figure 93. Argentina Chronic Hepatitis B Market Share (%), By Gender, 2017-2031F
  • Figure 94. Argentina Chronic Hepatitis B Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 95. Asia-Pacific Chronic Hepatitis B Market, By Value, in USD Billion, 2017-2031F
  • Figure 96. Asia-Pacific Chronic Hepatitis B Market, By Volume, in Million Units, 2017-2031F
  • Figure 97. Asia-Pacific Chronic Hepatitis B Market Share (%), By Drug Class, 2017-2031F
  • Figure 98. Asia-Pacific Chronic Hepatitis B Market Share (%), By Gender, 2017-2031F
  • Figure 99. Asia-Pacific Chronic Hepatitis B Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 100. Asia-Pacific Chronic Hepatitis B Market Share (%), By Country, 2017-2031F
  • Figure 101. India Chronic Hepatitis B Market, By Value, in USD Billion, 2017-2031F
  • Figure 102. India Chronic Hepatitis B Market, By Volume, in Million Units, 2017-2031F
  • Figure 103. India Chronic Hepatitis B Market Share (%), By Drug Class, 2017-2031F
  • Figure 104. India Chronic Hepatitis B Market Share (%), By Gender, 2017-2031F
  • Figure 105. India Chronic Hepatitis B Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 106. China Chronic Hepatitis B Market, By Value, in USD Billion, 2017-2031F
  • Figure 107. China Chronic Hepatitis B Market, By Volume, in Million Units, 2017-2031F
  • Figure 108. China Chronic Hepatitis B Market Share (%), By Drug Class, 2017-2031F
  • Figure 109. China Chronic Hepatitis B Market Share (%), By Gender, 2017-2031F
  • Figure 110. China Chronic Hepatitis B Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 111. Japan Chronic Hepatitis B Market, By Value, in USD Billion, 2017-2031F
  • Figure 112. Japan Chronic Hepatitis B Market, By Volume, in Million Units, 2017-2031F
  • Figure 113. Japan Chronic Hepatitis B Market Share (%), By Drug Class, 2017-2031F
  • Figure 114. Japan Chronic Hepatitis B Market Share (%), By Gender, 2017-2031F
  • Figure 115. Japan Chronic Hepatitis B Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 116. Australia Chronic Hepatitis B Market, By Value, in USD Billion, 2017-2031F
  • Figure 117. Australia Chronic Hepatitis B Market, By Volume, in Million Units, 2017-2031F
  • Figure 118. Australia Chronic Hepatitis B Market Share (%), By Drug Class, 2017-2031F
  • Figure 119. Australia Chronic Hepatitis B Market Share (%), By Gender, 2017-2031F
  • Figure 120. Australia Chronic Hepatitis B Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 121. Vietnam Chronic Hepatitis B Market, By Value, in USD Billion, 2017-2031F
  • Figure 122. Vietnam Chronic Hepatitis B Market, By Volume, in Million Units, 2017-2031F
  • Figure 123. Vietnam Chronic Hepatitis B Market Share (%), By Drug Class, 2017-2031F
  • Figure 124. Vietnam Chronic Hepatitis B Market Share (%), By Gender, 2017-2031F
  • Figure 125. Vietnam Chronic Hepatitis B Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 126. South Korea Chronic Hepatitis B Market, By Value, in USD Billion, 2017-2031F
  • Figure 127. South Korea Chronic Hepatitis B Market, By Volume, in Million Units, 2017-2031F
  • Figure 128. South Korea Chronic Hepatitis B Market Share (%), By Drug Class, 2017-2031F
  • Figure 129. South Korea Chronic Hepatitis B Market Share (%), By Gender, 2017-2031F
  • Figure 130. South Korea Chronic Hepatitis B Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 131. Indonesia Chronic Hepatitis B Market, By Value, in USD Billion, 2017-2031F
  • Figure 132. Indonesia Chronic Hepatitis B Market, By Volume, in Million Units, 2017-2031F
  • Figure 133. Indonesia Chronic Hepatitis B Market Share (%), By Drug Class, 2017-2031F
  • Figure 134. Indonesia Chronic Hepatitis B Market Share (%), By Gender, 2017-2031F
  • Figure 135. Indonesia Chronic Hepatitis B Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 136. Philippines Chronic Hepatitis B Market, By Value, in USD Billion, 2017-2031F
  • Figure 137. Philippines Chronic Hepatitis B Market, By Volume, in Million Units, 2017-2031F
  • Figure 138. Philippines Chronic Hepatitis B Market Share (%), By Drug Class, 2017-2031F
  • Figure 139. Philippines Chronic Hepatitis B Market Share (%), By Gender, 2017-2031F
  • Figure 140. Philippines Chronic Hepatitis B Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 141. Middle East & Africa Chronic Hepatitis B Market, By Value, in USD Billion, 2017-2031F
  • Figure 142. Middle East & Africa Chronic Hepatitis B Market, By Volume, in Million Units, 2017-2031F
  • Figure 143. Middle East & Africa Chronic Hepatitis B Market Share (%), By Drug Class, 2017-2031F
  • Figure 144. Middle East & Africa Chronic Hepatitis B Market Share (%), By Gender, 2017-2031F
  • Figure 145. Middle East & Africa Chronic Hepatitis B Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 146. Middle East & Africa Chronic Hepatitis B Market Share (%), By Country, 2017-2031F
  • Figure 147. Saudi Arabia Chronic Hepatitis B Market, By Value, in USD Billion, 2017-2031F
  • Figure 148. Saudi Arabia Chronic Hepatitis B Market, By Volume, in Million Units, 2017-2031F
  • Figure 149. Saudi Arabia Chronic Hepatitis B Market Share (%), By Drug Class, 2017-2031F
  • Figure 150. Saudi Arabia Chronic Hepatitis B Market Share (%), By Gender, 2017-2031F
  • Figure 151. Saudi Arabia Chronic Hepatitis B Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 152. UAE Chronic Hepatitis B Market, By Value, in USD Billion, 2017-2031F
  • Figure 153. UAE Chronic Hepatitis B Market, By Volume, in Million Units, 2017-2031F
  • Figure 154. UAE Chronic Hepatitis B Market Share (%), By Drug Class, 2017-2031F
  • Figure 155. UAE Chronic Hepatitis B Market Share (%), By Gender, 2017-2031F
  • Figure 156. UAE Chronic Hepatitis B Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 157. South Africa Chronic Hepatitis B Market, By Value, in USD Billion, 2017-2031F
  • Figure 158. South Africa Chronic Hepatitis B Market, By Volume, in Million Units, 2017-2031F
  • Figure 159. South Africa Chronic Hepatitis B Market Share (%), By Drug Class, 2017-2031F
  • Figure 160. South Africa Chronic Hepatitis B Market Share (%), By Gender, 2017-2031F
  • Figure 161. South Africa Chronic Hepatitis B Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 162. By Drug Class Map-Market Size (USD Billion) & Growth Rate (%), 2023
  • Figure 163. By Gender Map-Market Size (USD Billion) & Growth Rate (%), 2023
  • Figure 164. By Distribution Channel Map-Market Size (USD Billion) & Growth Rate (%), 2023
  • Figure 165. By Region Map-Market Size (USD Billion) & Growth Rate (%), 2023